Decision support for digital pathology
Philips and Definiens, a Germany-based company specialising in image analysis solutions, have signed a memorandum of understanding to jointly develop and market clinical decision support solutions for digital pathology.
The initial project between Philips and Definiens will focus on immunohistology-based breast cancer diagnostics, which includes the detection of biomarkers HER2, Estrogen Receptor (ER), Progesterone Receptor (PR), Ki67 and p53. Philips and Definiens also plan to investigate solutions for other cancers such as prostate and colon cancer.
Currently, anatomic pathologists examine tissue slices, after treating them with appropriate stains, through a microscope. The aim of staining is to reveal specific biomarkers of disease — such as cancer-related proteins — or to enhance contrast.
According to Philips, digitisation of the images is now enabling the use of objective and quantitative image analysis tools. The expected benefits of this development include enhanced operational efficiency and productivity for pathology departments, and increased diagnostic confidence.
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Experts speculate over cause of Iberian power outages
The EU and UK will be moving towards using Grid Forming inverters with Energy Storage that has an inherent ability to act as a source of Infinite...